迪瑞醫療(300396.SZ):2項醫療器械產品取得CE認證證書
格隆匯3月26日丨迪瑞醫療(300396.SZ)公佈,公司的2項醫療器械產品於近日取得了CE認證證書,產品名稱為新型冠狀病毒IgG抗體檢測試劑盒(化學發光免疫分析法)、新型冠狀病毒IgM抗體檢測試劑盒(化學發光免疫分析法)。
上述新型冠狀病毒的抗體檢測產品為新冠肺炎的疑似患者、無症狀患者、密切接觸者、核酸檢測陰性者提供快速、便捷的現場檢測手段,有助於提高感染患者的檢出率,從而達到有效防控疫情的目的。新型冠狀病毒IgG抗體和IgM抗體檢測聯合新型冠狀病毒核酸檢測是目前診斷新型冠狀病毒感染的重要實驗室篩查方法。
上述產品取得CE認證證書,表明了該產品符合歐盟相關要求,已經具備歐盟市場的准入條件,將進一步增強公司產品的綜合競爭力,助力新型冠狀病毒感染的疫情防控工作,對公司未來的經營將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.